PT  - JOURNAL ARTICLE
AU  - Dabrowski, Veronica
TI  - Use of Probiotics in the Prevention of Clostridioides difficile Infections during Antibiotic Exposure: A Systematic Review and Meta-Analysis
AID  - 10.1101/2023.10.04.23296557
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.04.23296557
4099  - http://medrxiv.org/content/early/2023/10/05/2023.10.04.23296557.short
4100  - http://medrxiv.org/content/early/2023/10/05/2023.10.04.23296557.full
AB  - Clostridioides difficile infections are a growing concern in the hospital setting. Current prevention methods include infection control strategies, antibiotic stewardship, and proper hand hygiene. However, the occurrence of C. difficile still manages to cause nosocomial outbreaks especially in vulnerable populations. Probiotics have been historically questioned for their use in the prevention of antibiotic-associated diarrhea and more specifically, C. difficile infections.This meta-analysis pools 10 randomized controlled trials for the prevention of Clostridioides difficile infections (CDI) from reviewing the Cochrane Central Register of Controlled Trials (CENTRAL). A priori inclusion criteria remained as follows: RCTs, blinded/open trials, all populations, articles, or conference abstracts. Exclusion criteria excluded publications published outside 2013-2023*, non-English language trials, pre-clinical trials/protocols, case reports/series/systematic reviews, duplicates, probiotics not specified in methods, non-RCTs, incomplete/no outcomes reported, no confirmation of Clostridioides difficile infection. Probiotic strains tested in these trials mainly included Lactobacillus spp. and Bifidobacterium spp. Some studies showed significant benefits while others did not find significant improvement in the prevention of C. difficile infections.The meta-analysis suggests that probiotics may have a positive effect in preventing CDI during antibiotic treatment. The study results had large levels of statistical heterogeneity which indicates an argument for further large-scale research to provide more definitive evidence on the efficacy of probiotics in CDI prevention.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.